3-(4-methyl-2,5-dioxoimidazolidin-4-yl)benzonitrile | 916210-71-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: 3-(4-methyl-2,5-dioxoimidazolidin-4-yl)benzonitrile
• CAS: 916210-71-4
• 化学式: C₁₁H₉N₃O₂
• mdl: MFCD16547555
• 分子量: 215.211
• InChiKey: WUIGRSIAJLDKLZ-UHFFFAOYSA-N

物化性质

• 密度：
  1.37±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.181
• 拓扑面积：
  82
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(4-methyl-2,5-dioxoimidazolidin-4-yl)benzonitrile 、 溶剂黄146 在 palladium 10% on activated carbon 氢气 作用下， 以 乙醇 为溶剂， 生成 Acetic acid;5-[3-(aminomethyl)phenyl]-5-methylimidazolidine-2,4-dione
  参考文献：
  名称：

  Multicyclic bis-amide MMP inhibitors

  摘要：

  本发明总体涉及含有双酰胺基团的药物制剂，特别是多环双酰胺MMP-13抑制剂化合物。更具体地，本发明提供了一类新型的MMP-13抑制化合物，它们含有与杂环部分结合的嘧啶基双酰胺基团，与目前已知含双酰胺基团的MMP-13抑制剂相比，显示出增加的活性和溶解度。

  公开号：

  US20060173183A1
• 作为产物：
  描述：

  氰化钠 、 碳酸氢铵 、 3-乙酰苯腈 以 乙醇 、 水 为溶剂， 生成 3-(4-methyl-2,5-dioxoimidazolidin-4-yl)benzonitrile
  参考文献：
  名称：

  Multicyclic bis-amide MMP inhibitors

  摘要：

  本发明总体涉及含有双酰胺基团的药物制剂，特别是多环双酰胺MMP-13抑制剂化合物。更具体地，本发明提供了一类新型的MMP-13抑制化合物，它们含有与杂环部分结合的嘧啶基双酰胺基团，与目前已知含双酰胺基团的MMP-13抑制剂相比，显示出增加的活性和溶解度。

  公开号：

  US20060173183A1

文献信息

• Identification and Profiling of Hydantoins—A Novel Class of Potent Antimycobacterial DprE1 Inhibitors
  作者：Maciej K. Rogacki、Eleni Pitta、Olga Balabon、Sophie Huss、Eva Maria Lopez-Roman、Argyrides Argyrou、Delia Blanco-Ruano、Monica Cacho、Christophe M. L. Vande Velde、Koen Augustyns、Lluis Ballell、David Barros、Robert H. Bates、Fraser Cunningham、Pieter Van der Veken

  DOI：10.1021/acs.jmedchem.8b01356

  日期：2018.12.27

  Tuberculosis is the leading cause of death worldwide from infectious diseases. With the development of drug-resistant strains of Mycobacterium tuberculosis, there is an acute need for new medicines with novel modes of action. Herein, we report the discovery and profiling of a novel hydantoin-based family of antimycobacterial inhibitors of the decaprenylphospho-beta-D-ribofuranose 2-oxidase (DprE1). In this study, we have prepared a library of more than a 100 compounds and evaluated them for their biological and physicochemical properties. The series is characterized by high enzymatic and whole-cell activity, low cytotoxicity, and a good overall physicochemical profile. In addition, we show that the series acts via reversible inhibition of the DprE1 enzyme. Overall, the novel compound family forms an attractive base for progression to further stages of optimization and may provide a promising drug candidate in the future.
• Heterobicyclic metalloprotease inhibitors
  申请人：Steeneck Christoph

  公开号：US20070155738A1

  公开（公告）日：2007-07-05

  The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
• Heterobicyclic Metalloprotease Inhibitors
  申请人：STEENECK Christoph

  公开号：US20090312312A1

  公开（公告）日：2009-12-17

  The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
• HETEROBICYCLIC METALLOPROTEASE INHIBITORS
  申请人：Steeneck Christoph

  公开号：US20120015920A1

  公开（公告）日：2012-01-19

  The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
• US7795245B2
  申请人：——

  公开号：US7795245B2

  公开（公告）日：2010-09-14